CONTEXT: Major depressive disorder in adolescents is common and impairing. Efficacious treatments have been developed, but little is known about longer-term outcomes, including recurrence. OBJECTIVES: To determine whether adolescents who responded to short-term treatments or who received the most efficacious short-term treatment would have lower recurrence rates, and to identify predictors of recovery and recurrence. DESIGN: Naturalistic follow-up study. SETTING: Twelve academic sites in the United States. PARTICIPANTS: One hundred ninety-six adolescents (86 males and 110 females) randomized to 1 of 4 short-term interventions (fluoxetine hydrochloride treatment, cognitive behavioral therapy, their combination, or placebo) in the Treatment for Adolescents With Depression Study were followed up for 5 years after study entry (44.6% of the original Treatment for Adolescents With Depression Study sample). MAIN OUTCOME MEASURES: Recovery was defined as absence of clinically significant major depressive disorder symptoms on the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version interview for at least 8 weeks, and recurrence was defined as a new episode of major depressive disorder following recovery. RESULTS: Almost all participants (96.4%) recovered from their index episode of major depressive disorder during the follow-up period. Recovery by 2 years was significantly more likely for short-term treatment responders (96.2%) than for partial responders or nonresponders (79.1%) (P < .001) but was not associated with having received the most efficacious short-term treatment (the combination of fluoxetine and cognitive behavioral therapy). Of the 189 participants who recovered, 88 (46.6%) had a recurrence. Recurrence was not predicted by full short-term treatment response or by original treatment. However, full or partial responders were less likely to have a recurrence (42.9%) than were nonresponders (67.6%) (P = .03). Sex predicted recurrence (57.0% among females vs 32.9% among males; P = .02). CONCLUSIONS: Almost all depressed adolescents recovered. However, recurrence occurs in almost half of recovered adolescents, with higher probability in females in this age range. Further research should identify and address the vulnerabilities to recurrence that are more common among young women.
RCT Entities:
CONTEXT: Major depressive disorder in adolescents is common and impairing. Efficacious treatments have been developed, but little is known about longer-term outcomes, including recurrence. OBJECTIVES: To determine whether adolescents who responded to short-term treatments or who received the most efficacious short-term treatment would have lower recurrence rates, and to identify predictors of recovery and recurrence. DESIGN: Naturalistic follow-up study. SETTING: Twelve academic sites in the United States. PARTICIPANTS: One hundred ninety-six adolescents (86 males and 110 females) randomized to 1 of 4 short-term interventions (fluoxetine hydrochloride treatment, cognitive behavioral therapy, their combination, or placebo) in the Treatment for Adolescents With Depression Study were followed up for 5 years after study entry (44.6% of the original Treatment for Adolescents With Depression Study sample). MAIN OUTCOME MEASURES: Recovery was defined as absence of clinically significant major depressive disorder symptoms on the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version interview for at least 8 weeks, and recurrence was defined as a new episode of major depressive disorder following recovery. RESULTS: Almost all participants (96.4%) recovered from their index episode of major depressive disorder during the follow-up period. Recovery by 2 years was significantly more likely for short-term treatment responders (96.2%) than for partial responders or nonresponders (79.1%) (P < .001) but was not associated with having received the most efficacious short-term treatment (the combination of fluoxetine and cognitive behavioral therapy). Of the 189 participants who recovered, 88 (46.6%) had a recurrence. Recurrence was not predicted by full short-term treatment response or by original treatment. However, full or partial responders were less likely to have a recurrence (42.9%) than were nonresponders (67.6%) (P = .03). Sex predicted recurrence (57.0% among females vs 32.9% among males; P = .02). CONCLUSIONS: Almost all depressed adolescents recovered. However, recurrence occurs in almost half of recovered adolescents, with higher probability in females in this age range. Further research should identify and address the vulnerabilities to recurrence that are more common among young women.
Authors: J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-07 Impact factor: 8.829
Authors: G J Emslie; A J Rush; W A Weinberg; C M Gullion; J Rintelmann; C W Hughes Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-06 Impact factor: 8.829
Authors: Betsy D Kennard; Susan G Silva; Simon Tonev; Paul Rohde; Jennifer L Hughes; Benedetto Vitiello; Christopher J Kratochvil; John F Curry; Graham J Emslie; Mark Reinecke; John March Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-02 Impact factor: 8.829
Authors: Elizabeth McCauley; Gretchen Gudmundsen; Kelly Schloredt; Christopher Martell; Isaac Rhew; Samuel Hubley; Sona Dimidjian Journal: J Clin Child Adolesc Psychol Date: 2015-01-20
Authors: Joan Rosenbaum Asarnow; Martha C Tompson; Alexandra M Klomhaus; Kalina Babeva; David A Langer; Catherine A Sugar Journal: J Child Psychol Psychiatry Date: 2019-12-15 Impact factor: 8.982
Authors: Matti Cervin; Lesley A Norris; Golda Ginsburg; Elizabeth A Gosch; Scott N Compton; John Piacentini; Anne Marie Albano; Dara Sakolsky; Boris Birmaher; Courtney Keeton; Eric A Storch; Philip C Kendall Journal: J Am Acad Child Adolesc Psychiatry Date: 2020-09-17 Impact factor: 8.829
Authors: Amy T Peters; Rachel H Jacobs; Claudia Feldhaus; David B Henry; Anne Marie Albano; Scott A Langenecker; Mark A Reinecke; Susan G Silva; John F Curry Journal: J Adolesc Health Date: 2015-11-11 Impact factor: 5.012